Search research articles
Contact Us
Filters
Showing results (251-260 of 256) with videos related to
Page
of 26
Sort By:
You have reached the last page of results.
This site can display upto 256 results.
Journal of Cell Science
|
November 6, 2024
Decreased DNA density is a better indicator of a nuclear bleb than lamin B loss
Samantha Bunner, Kelsey Prince, Emily M Pujadas Liwag, et al.
Molecular Cancer Therapeutics
|
February 1, 2015
The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
Paul Foster, Kyoko Yamaguchi, Pin P Hsu, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 7, 2012
The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors
Moon H Kim, Amy Lew Tsuhako, Erick W Co, et al.
Journal of Medicinal Chemistry
|
December 19, 2022
Discovery of a Series of Potent, Selective, and Orally Bioavailable Nucleoside Inhibitors of CD73 That Demonstrates <i>In Vivo</i> Antitumor Activity
Jim Li, Lijing Chen, Roland J Billedeau, et al.
Nature Communications
|
September 9, 2022
In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response
Aditi Sahu, Kivanc Kose, Lukas Kraehenbuehl, et al.
JACC. Asia
|
March 21, 2026
Myocardial Infarction Without Standard Modifiable Risk Factors From 2025-2040: Forecast Analysis of Multinational, Population-Based Study
Grace Cao, Nicholas Weight, Silingga Metta Jauhari, et al.
Page
of 26
Search research articles
Search
Showing results (251-260 of 256) with videos related to
Sort By:
Page
of 26
You have reached the last page of results.
This site can display upto 256 results.
Journal of Cell Science
|
November 6, 2024
Decreased DNA density is a better indicator of a nuclear bleb than lamin B loss
Samantha Bunner, Kelsey Prince, Emily M Pujadas Liwag, et al.
Molecular Cancer Therapeutics
|
February 1, 2015
The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
Paul Foster, Kyoko Yamaguchi, Pin P Hsu, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 7, 2012
The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors
Moon H Kim, Amy Lew Tsuhako, Erick W Co, et al.
Journal of Medicinal Chemistry
|
December 19, 2022
Discovery of a Series of Potent, Selective, and Orally Bioavailable Nucleoside Inhibitors of CD73 That Demonstrates <i>In Vivo</i> Antitumor Activity
Jim Li, Lijing Chen, Roland J Billedeau, et al.
Nature Communications
|
September 9, 2022
In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response
Aditi Sahu, Kivanc Kose, Lukas Kraehenbuehl, et al.
JACC. Asia
|
March 21, 2026
Myocardial Infarction Without Standard Modifiable Risk Factors From 2025-2040: Forecast Analysis of Multinational, Population-Based Study
Grace Cao, Nicholas Weight, Silingga Metta Jauhari, et al.
Page
of 26